de-Sousa F C, Marinho M M, Aguiar G V, Viana G S
Departamento de Fisiologia e Farmacologia, Centro de Ciências da Saúde, Universidade Federal do Ceará, Fortaleza, CE, Brasil.
Braz J Med Biol Res. 1995 Jan;28(1):113-9.
The effects of pimozide, mazindol and apomorphine on muscarinic receptors in homogenates of rat cerebral motor cortex were measured by binding assays, using 3H-N-methylscopolamine (3H-NMS) alone as ligand (for the measurement of M1- and M2-like receptors) or in the presence of carbachol or pirenzepine for determination of M1- and M2-like receptors, respectively. Female Wistar rats (150 g) were treated daily for one week with pimozide, a dopaminergic antagonist (10 and 20 mg/kg, po, by gavage), or with apomorphine (1 mg/kg, ip). In another set of experiments, animals were treated with pimozide and 30 min later with mazindol (10 mg/kg, po, by gavage) or apomorphine. The drugs were administered daily for one week. Controls received the same volume of saline. 3H-NMS binding was increased from the control value of 418 +/- 17 to 548 +/- 42 fmol/mg protein by administration of mazindol (10 mg/kg) but binding was reduced to 360 +/- 11 fmol/mg protein upon administration of pimozide (20 mg/kg) plus mazindol (10 mg/kg). Similarly 10 mg/kg pimozide reduced the increase in M1-like receptors caused by mazindol from 262 +/- 31 to 220 +/- 20 fmol/mg protein. Although 20 mg/kg pimozide alone produced a decrease in M1- plus M2-like receptors (from 418 +/- 17 to 348 +/- 22 fmol/mg protein), its action was preferentially on M2-like receptors, decreasing them from 148 +/- 10 to 111 +/- 15 fmol/mg protein in the control and treated groups, respectively. At the higher dose, 20 mg/kg pimozide also inhibited the 3H-NMS binding (M1- plus M2-like receptors) in the presence of apomorphine (263 +/- 25 vs 418 +/- 17 fmol/mg protein.(ABSTRACT TRUNCATED AT 250 WORDS)
通过结合试验测量了匹莫齐特、马吲哚和阿扑吗啡对大鼠大脑运动皮质匀浆中毒蕈碱受体的影响,单独使用³H-N-甲基东莨菪碱(³H-NMS)作为配体(用于测量M1样和M2样受体),或分别在存在卡巴胆碱或哌仑西平的情况下用于测定M1样和M2样受体。雌性Wistar大鼠(150克)每天用多巴胺能拮抗剂匹莫齐特(10和20毫克/千克,经口灌胃)或阿扑吗啡(1毫克/千克,腹腔注射)治疗一周。在另一组实验中,动物先用匹莫齐特治疗,30分钟后再用马吲哚(10毫克/千克,经口灌胃)或阿扑吗啡治疗。药物每天给药一周。对照组给予相同体积的生理盐水。给予马吲哚(10毫克/千克)后,³H-NMS结合从对照值418±17增加到548±42飞摩尔/毫克蛋白质,但给予匹莫齐特(20毫克/千克)加马吲哚(10毫克/千克)后,结合减少到360±11飞摩尔/毫克蛋白质。同样,10毫克/千克匹莫齐特使马吲哚引起的M1样受体增加从262±31减少到220±20飞摩尔/毫克蛋白质。虽然单独使用20毫克/千克匹莫齐特会使M1样和M2样受体减少(从418±17减少到348±22飞摩尔/毫克蛋白质),但其作用主要针对M2样受体,在对照组和治疗组中分别从148±10减少到111±15飞摩尔/毫克蛋白质。在较高剂量下,20毫克/千克匹莫齐特在存在阿扑吗啡的情况下也抑制³H-NMS结合(M1样和M2样受体)(263±25对418±17飞摩尔/毫克蛋白质)。(摘要截断于250字)